In this evidence-based guide, Scott Mazza, co-founder and COO of Vitality CBD, outlines emerging research and best practices for the responsible use of CBD in pets. The article reviews veterinary studies indicating that hemp-derived cannabinoids are generally well tolerated in dogs and cats at appropriate doses, with potential applications for conditions such as arthritis, anxiety, pain, and epilepsy. Mazza emphasizes careful dosing, species-specific formulations, veterinarian guidance, and rigorous product standards, including full-spectrum extracts and third-party testing, to ensure safety and efficacy for companion animals.

In this wellness-focused feature, Scott Mazza, co-founder and COO of Vitality CBD, reviews emerging research on CBD’s effects on exercise performance, anxiety, and perceived exertion. Drawing on peer-reviewed studies, the article explains how CBD may reduce exercise-related anxiety and improve subjective workout experiences without impairing performance, while also examining its potential role in recovery, inflammation, and sleep. Mazza emphasizes cautious adoption, product quality, and third-party testing as athletes and professional sports organizations increasingly evaluate cannabis compounds within training and wellness routines.

In this industry analysis, Scott Mazza, co-founder and COO of Vitality CBD, examines the scientific, legal, and regulatory uncertainties surrounding delta-8 THC as policymakers revisit the Farm Bill. The article explains how delta-8 is synthesized from hemp-derived CBD, outlines early findings on its milder psychoactive profile, and contrasts anecdotal consumer use with the current lack of rigorous clinical research. Mazza argues for science-based regulation focused on production standards and consumer safety, warning that outright prohibition could harm the hemp industry while failing to address the risks posed by poor manufacturing practices.

In this guest column, Scott Mazza, co-founder and COO of Vitality CBD, examines how advances in cannabis-based pain research are accelerating mainstream acceptance of cannabis and its compounds. Citing peer-reviewed studies on terpenes matching or exceeding morphine’s effects in neuropathic pain models, along with growing evidence around CBD’s role in pain modulation and opioid-related harm reduction, the article frames pain management as a central driver of cultural, medical, and legislative change. Mazza connects emerging science, professional sports adoption, and shifting public opinion to argue that effective, non-addictive pain treatments may be the key catalyst for broader cannabis normalization.

In this comparative analysis, Scott Mazza, co-founder and COO of Vitality CBD, examines the physiological and therapeutic differences between CBD and THC across anxiety, sleep, pain, and arthritis applications. Drawing on clinical trials and observational studies, the article explains how THC’s sedative and analgesic effects contrast with CBD’s non-psychoactive role in anxiety reduction, inflammation control, and sleep regulation, while noting evidence for combined formulations in certain pain contexts. Mazza emphasizes informed, condition-specific selection, cautious dosing, and the potential role of full-spectrum products, underscoring the need for continued research and responsible use.

Benzinga examines how cannabis policy could influence voter turnout and party alignment in the 2024 U.S. election. Scott Mazza of Vitality CBD weighs in on the limitations of rescheduling and the broader implications of descheduling. A timely, political lens on cannabis reform and its electoral stakes.

In this science-focused article, Scott Mazza, co-founder and COO of Vitality CBD, reviews emerging research on CBD’s potential role in supporting women during menopause. Drawing on clinical and observational studies, the piece examines how CBD may help address common symptoms such as sleep disruption, joint pain, anxiety, and mood changes, while emphasizing evidence around full-spectrum formulations and dosing. Mazza also highlights the importance of product quality, third-party testing, and cautious application as scientific understanding and regulatory oversight continue to evolve.

In this April 2024 feature for The Bluntness, Scott Mazza, co-founder and COO of Vitality CBD, explains the role cannabinoids play within the entourage effect, alongside terpenes and flavonoids. The article outlines how different cannabinoids, ranging from THC and CBD to lesser-known compounds like CBG and CBN, interact with the endocannabinoid system and with each other to shape therapeutic and experiential outcomes. Citing emerging research and a 2022 clinical trial, Mazza highlights why full-spectrum CBD products may deliver effects at lower doses, reinforcing the importance of compound synergy, product composition, and informed consumer experimentation.

In this April 2024 analysis, Scott Mazza, co-founder and COO of Vitality CBD, examines emerging research comparing CBD and THC for anxiety management. Drawing on a four-week study of 300 participants published in Cannabis and Cannabinoid Research, the article reports that CBD-dominant formulations produced the most consistent anxiety reduction with fewer cognitive side effects than THC-dominant products. Mazza underscores the importance of dosing, product quality, and third-party testing, positioning CBD as a well-tolerated, evidence-supported option while emphasizing the need for continued clinical research.

In this article, Scott Mazza reviews emerging scientific evidence that begins to establish evidence-based daily intake limits for CBD, addressing a long-standing gap in consumer safety guidance. Drawing on a 2023 toxicological review and recent clinical findings, the article outlines proposed upper limits for different adult populations, including stricter thresholds for pregnancy, lactation, and liver risk. Mazza frames these dosage benchmarks as a critical step toward clearer labeling, improved regulatory decision-making, and a more mature, science-led CBD industry.

In this guest column, Scott Mazza examines emerging peer-reviewed research supporting the cannabis “entourage effect,” arguing that cannabinoids, terpenes, and flavonoids interact synergistically to influence therapeutic outcomes beyond isolated compounds alone. Citing findings published in Molecules, the article explains how these interactions may shape analgesic, anti-inflammatory, and neuroprotective effects, while also highlighting the need for further research to clarify compound-specific contributions. Mazza situates these findings within a broader shift toward whole-plant and chemistry-driven approaches to cannabis formulation, treatment, and classification.

Scott Mazza examines the hemp industry’s leading regulatory priorities ahead of the upcoming Farm Bill, including classifying CBD as a conventional dietary supplement and food ingredient, easing testing bottlenecks, and adjusting federal THC limits for hemp. Drawing on current FDA, USDA, and industry positions, the article argues that existing regulatory frameworks can address safety and quality concerns without creating new, uncertain pathways. The piece frames these proposals as pragmatic, farmer-focused adjustments aimed at stabilizing the CBD market and providing clearer federal guidance.